Ziltivekimab对慢性肾脏病患者心血管疾病和炎症反应的疗效研究

Study of the Efficacy of Ziltivekimab on Cardiovascular Disease and Inflammatory Response in Patients with Chronic Kidney Disease

目的:评价Ziltivekimab对CKD患者的心血管疾病和炎症反应的临床疗效。方法:计算机检索PubMed、PubMed、Embase、MEDLINE、Clinical Trials Website、Cochrane Library、中国知网(CNKI)、万方、维普等数据库中关于Ziltivekimab治疗CKD患者的心血管疾病和慢性炎症有效性的RCTs,对纳入文献进行数据提取,用Cochrane偏倚风险评估工具进行偏倚风险评估,采用RevMan 5.3软件对数据进行meta分析。结果:纳入3篇RCTs,共334例CKD患者。Meta分析结果显示,Ziltivekimab试验组的hsCRP(P=0.01),SAA(P<0.000 01),纤维蛋白原(P<0.000 01),LDL-C(P<0.000 01),HDL-C(P=0.04)改善情况优于对照组。结论:Ziltivekimab能降低慢性炎症和动脉粥样硬化的生物标志物,有效减少CKD患者的心血管疾病和炎症反应风险。

Objective:To evaluate the clinical efficacy of Ziltivekimab on cardiovascular disease and inflammatory response in patients with CKD.Methods:All randomized controlled trials about the validity of treatingcardiovascular disease and chronic inflammation in patients with CKD by Ziltivekimab were searched and retrieved from the databases including PubMed,Embase,MEDLINE,Clinical Trials Website,Cochrane Library,China Knowledge Network(CNKI),Wanfang,and Vipul databases Thedata were extracted Quality was assessed using the Cochrane Risk of Bias Assessment Tool.Meta-analysis was performed by RevMan5.3.Results:There were 3 RCTs involving334 patients with CKD were included.The meta-analysis results showed that the hsCRP(P=0.01),SAA(P<0.000 01),fibrinogen(P<0.000 01),LDL-C(P<0.000 01),HDL-C(P=0.04) in trial group improved better than the control group.Conclusion:Ziltivekimab effectively reduces the risk of cardiovascular disease and inflammatory response in patients with CKD.